Abstract：
To investigate the safety and efficacy of iodine-125 seed implantation in the treatment of abdomen-thorax desmoid tumors (DTs).
Data from 14 DT patients who received brachytherapy with iodine-125 seeds were retrospectively collected from 2014 to 2020. The operation was completed using CT guidance and the treatment plan system (TPS). The number of lesions and the target dosimetry parameters were recorded. After brachytherapy, the lesions were evaluated using response evaluation criteria in solid tumors (RECIST).
Fourteen patients with 18 lesions were enrolled in this study; eleven lesions were in the thorax, seven were in the abdomen, and the lesion gross tumor volume (GTV) was 82.10 cc (interquartile range [IQR]: 40.37, 203.42 cc). The median number of seeds was 88 (IQR: 35, 158), and the median prescription dose was 120 Gy (IQR: 115, 120 Gy). The D90 was 123 ± 16.7 Gy, the V90 was 97% (IQR: 95.00, 97.25%), and the V200 was 27% (IQR: 14.50, 33.00%). The median follow-up time for each lesion was 34 (IQR: 23, 67) months, and the local response rate was 100%. Following brachytherapy, the overall survival was 52.3 ± 30.72 months. One year after brachytherapy, one patient experienced persistent worsening of a brachial plexus injury; another received a ureteral stent. No brachytherapy-related complications were observed in the remaining patients.
Iodine-125 brachytherapy is a novel treatment option for DT of the abdomen and thorax. Although it is a safe and effective treatment, the radiation dose of iodine-125 brachytherapy for DT-embedded organs at risk must be investigated further.
Data from 14 DT patients who received brachytherapy with iodine-125 seeds were retrospectively collected from 2014 to 2020. The operation was completed using CT guidance and the treatment plan system (TPS). The number of lesions and the target dosimetry parameters were recorded. After brachytherapy, the lesions were evaluated using response evaluation criteria in solid tumors (RECIST).
Fourteen patients with 18 lesions were enrolled in this study; eleven lesions were in the thorax, seven were in the abdomen, and the lesion gross tumor volume (GTV) was 82.10 cc (interquartile range [IQR]: 40.37, 203.42 cc). The median number of seeds was 88 (IQR: 35, 158), and the median prescription dose was 120 Gy (IQR: 115, 120 Gy). The D90 was 123 ± 16.7 Gy, the V90 was 97% (IQR: 95.00, 97.25%), and the V200 was 27% (IQR: 14.50, 33.00%). The median follow-up time for each lesion was 34 (IQR: 23, 67) months, and the local response rate was 100%. Following brachytherapy, the overall survival was 52.3 ± 30.72 months. One year after brachytherapy, one patient experienced persistent worsening of a brachial plexus injury; another received a ureteral stent. No brachytherapy-related complications were observed in the remaining patients.
Iodine-125 brachytherapy is a novel treatment option for DT of the abdomen and thorax. Although it is a safe and effective treatment, the radiation dose of iodine-125 brachytherapy for DT-embedded organs at risk must be investigated further.
摘要：
目的：探讨125碘粒子植入治疗腹部-胸部纤维瘤(DTs)的安全性和有效性。
方法：回顾性收集了2014年至2020年接受碘-125种子近距离放射治疗的14例DT患者的数据。使用CT引导和治疗计划系统（TPS）完成手术。记录病变的数量和目标剂量学参数。近距离放射治疗后,使用实体瘤的应答评估标准(RECIST)评估病变.
结果：本研究纳入14例患者，18个病灶；11个病灶位于胸部，七个人在腹部，病灶的大体肿瘤体积(GTV)为82.10cc(四分位距[IQR]:40.37,203.42cc)。种子的中位数是88（IQR：35，158），中位处方剂量为120Gy(IQR:115,120Gy)。D90为123±16.7Gy，V90为97%（IQR：95.00，97.25%），V200为27%(IQR:14.50,33.00%)。每个病灶的中位随访时间为34(IQR:23、67)个月,当地反应率为100%。近距离放射治疗后,总生存期为52.3±30.72个月.近距离放射治疗一年后,一名患者臂丛神经损伤持续恶化;另一名患者接受了输尿管支架治疗.其余患者未观察到近距离放射治疗相关并发症。
结论：碘-125近距离放射治疗是一种新的腹部和胸部DT治疗选择。虽然它是一种安全有效的治疗方法，必须进一步研究碘-125近距离放射治疗对有风险的DT包埋器官的辐射剂量.
方法：回顾性收集了2014年至2020年接受碘-125种子近距离放射治疗的14例DT患者的数据。使用CT引导和治疗计划系统（TPS）完成手术。记录病变的数量和目标剂量学参数。近距离放射治疗后,使用实体瘤的应答评估标准(RECIST)评估病变.
结果：本研究纳入14例患者，18个病灶；11个病灶位于胸部，七个人在腹部，病灶的大体肿瘤体积(GTV)为82.10cc(四分位距[IQR]:40.37,203.42cc)。种子的中位数是88（IQR：35，158），中位处方剂量为120Gy(IQR:115,120Gy)。D90为123±16.7Gy，V90为97%（IQR：95.00，97.25%），V200为27%(IQR:14.50,33.00%)。每个病灶的中位随访时间为34(IQR:23、67)个月,当地反应率为100%。近距离放射治疗后,总生存期为52.3±30.72个月.近距离放射治疗一年后,一名患者臂丛神经损伤持续恶化;另一名患者接受了输尿管支架治疗.其余患者未观察到近距离放射治疗相关并发症。
结论：碘-125近距离放射治疗是一种新的腹部和胸部DT治疗选择。虽然它是一种安全有效的治疗方法，必须进一步研究碘-125近距离放射治疗对有风险的DT包埋器官的辐射剂量.
